FR Specialty: Policy and Access

Home›The Forward Review›Opioids for Back Pain: The OPAL Trial
The Forward Review Live Commentary Vol. I · 2026
Randomised Trial Volume 1 · 2026 Opioids Acute Back Pain
Do Opioids Actually Work for Back Pain? The Lancet OPAL Answer
For decades a short course of opioids was a routine answer to a badly hurting back. Then a large placebo-controlled trial in The Lancet put that answer to the test. Here is the honest read of what OPAL found, why it matters for anyone in acute pain, and what the evidence points to instead.
Jason Forward, DC, Vanguard Chiropractic, Tulsa, Oklahoma Published July 7, 2026
✓ Medically reviewed by Dr. Jason Forward, DC, July 2026. Last updated July 2026.
Reviewing
Jones CMP, Day RO, Koes BW, Latimer J, Maher CG, et al. Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial. The Lancet. 2023;402(10398):304-312.
DOI: 10.1016/S0140-6736(23)00404-X · PMID: 37392748
Key Points
The OPAL trial randomly assigned 347 adults with acute low back or neck pain to a real opioid or an identical placebo, on top of standard care, across 157 clinics and emergency departments in Sydney (Jones and colleagues, 2023).
At 6 weeks, pain was no better on the opioid than on placebo. The adjusted difference was 0.53 points on a 0 to 10 scale, favoring placebo, and it was not statistically significant (95% CI -0.00 to 1.07, p=0.051).
The opioid also failed to beat placebo on physical function, quality of life, and time to recovery. There was no measurable upside.
At 1 year, the opioid group had slightly worse pain and double the risk of opioid misuse: 20 percent versus 10 percent on a standard misuse screen (Jones and colleagues, 2023).
Major guidelines already put non-drug care first. The American College of Physicians names spinal manipulation, heat, massage, and exercise ahead of medication for back pain (Qaseem and colleagues, 2017).
This is not a case against any clinician. It is the strongest available evidence pointing patients and doctors toward first-line conservative care. At Vanguard Chiropractic, one honest version of that is a $40 walk-in adjustment, one tool among several.
Plain Language Summary
If a doctor once gave you a few days of opioids for a badly hurting back or neck, that made sense under the old assumptions. A large 2023 trial called OPAL tested those assumptions head to head against a placebo, a pill with no medicine in it, and the opioid did not win. At 6 weeks the two groups had the same pain.
The follow-up made the picture worse, not better. A year later, the people who had taken the opioid reported slightly more pain, and they were twice as likely to show signs of opioid misuse. So the drug carried real risk and gave no real edge for this kind of pain.
None of this means your pain is not real or that you did anything wrong by taking what you were prescribed. It means the evidence now points to non-drug care first: movement, time, and hands-on treatment. At Vanguard, that starts at $40, no contract, and you can stop any time.
Why This Question Matters
Low back and neck pain are among the most common reasons adults visit a doctor or an emergency room, and opioids were long a default answer. Knowing whether opioids for back pain actually outperform a placebo is one of the most practical safety questions in everyday medicine, because the wrong answer carries a real dependence risk.
"The question was never whether the pain is real. It is whether the opioid does anything the sugar pill does not."
Acute low back and neck pain send an enormous number of people through primary care and emergency rooms every year. For a long time, a short opioid script was a normal part of that visit, built on a reasonable-sounding assumption: strong pain calls for a strong painkiller. The trouble is that assumption was never tested cleanly against a placebo in this exact setting, so nobody actually knew whether the opioid earned its place or just rode along with the natural recovery that most acute back pain follows anyway.
That gap matters because opioids are not a free lunch. They carry a known risk of dependence and misuse, even after a short course, and the human cost of getting that trade-off wrong is severe. So the practical question is not academic. If the drug does not clearly beat a placebo for this kind of pain, then the risk sits on one side of the scale with very little on the other. The OPAL trial was built to weigh exactly that.
How the OPAL Trial Was Built
OPAL was a triple-blind, placebo-controlled randomised trial, the strongest design in clinical research. Researchers enrolled 347 adults with up to 12 weeks of acute low back or neck pain from 157 primary care and emergency sites in Sydney, then randomly gave half a real opioid and half an identical dummy pill for up to 6 weeks.
The Lancet published OPAL, short for Opioid Analgesia for acute Low back and neck pain, in 2023 (Jones and colleagues, 2023). The team recruited 347 adults presenting to one of 157 primary care practices or emergency departments in Sydney, Australia, with recent low back pain, neck pain, or both, of at least moderate severity. Everyone received the same guideline-recommended care, which is reassurance, advice to stay active, and simple analgesia. On top of that, participants were randomly assigned to add either an opioid, oxycodone with naloxone at up to 20 milligrams of oxycodone per day, or a placebo made to look identical, for up to 6 weeks.
"Triple-blind means no one in the room knew who got the drug, which is exactly how you keep hope and expectation from masquerading as relief."
The design is what gives this study its weight. It was triple-blind, meaning the patients, the treating clinicians, and the outcome assessors were all kept unaware of who received the real opioid. That blinding is not a technicality. Pain is heavily shaped by expectation, and a placebo can produce genuine relief on its own. The only way to see whether an opioid does anything beyond that expectation effect is to compare it against an identical-looking placebo with everyone blinded. The primary question was simple: how much pain, on a 0 to 10 scale, would each group report at 6 weeks?
What Did OPAL Find at Six Weeks?
Nothing that favored the opioid. At 6 weeks, average pain was 2.78 on the opioid versus 2.25 on placebo, a 0.53-point gap that actually leaned toward placebo and was not statistically significant. The opioid also failed to beat placebo on physical function, quality of life, and how fast people recovered.
At the 6-week mark, the mean pain score was 2.78 out of 10 in the opioid group and 2.25 in the placebo group (Jones and colleagues, 2023). The adjusted difference of 0.53 points not only failed to favor the opioid, it tilted slightly the other way, toward placebo, and it did not reach statistical significance (95% CI -0.00 to 1.07, p=0.051). In plain terms, the group taking a real opioid did not feel better than the group taking a dummy pill. Both improved, because most acute back and neck pain improves with time and sensible care, but the drug added nothing detectable to that recovery.
OPAL Trial: Opioid vs Placebo at 6 Weeks
Outcome Opioid Group Placebo Group
Mean pain (0 to 10) 2.78 2.25
Better physical function? No advantage No advantage
Better quality of life? No advantage No advantage
Faster recovery? No advantage No advantage
"A real opioid did not out-relieve a pill with no medicine in it. That single sentence should reset how we treat a hurting back."
The absence of benefit ran across every outcome the researchers checked, not just pain. Physical function, quality of life, and time to recovery all came out the same in both groups. When a powerful drug shows no edge over placebo on a single well-run trial of this size, that is a strong signal. When it shows no edge on every outcome measured, the signal is hard to argue with.
What Happened at One Year?
The one-year follow-up turned a null result into a cautionary one. People who had taken the opioid reported slightly worse pain than the placebo group, and they were twice as likely to show signs of opioid misuse: 20 percent versus 10 percent on a validated screening measure. The short course left a longer shadow.
A trial that only reported the 6-week tie would already argue against opioids here, because a drug with real risks and no proven benefit is a bad trade. OPAL went further and followed participants out to 52 weeks. At one year, the opioid group did not just fail to pull ahead. They reported slightly worse pain than the placebo group (Jones and colleagues, 2023).
The safety signal is the part I want patients to sit with. At 52 weeks, 24 of 123 people in the opioid group, about 20 percent, screened positive for risk of opioid misuse on the Current Opioid Misuse Measure, a standard validated questionnaire. In the placebo group it was 13 of 128, about 10 percent. That is double the misuse risk, traced back to a short, guideline-style course of medication for ordinary acute pain. The authors concluded plainly that opioids should not be recommended for acute non-specific low back or neck pain.
"A few weeks of pills for a sore back doubled the one-year misuse risk and bought no relief. That is the whole trade laid bare."
This is also where the OPAL result connects to the wider record on conservative care. In a separate Forward Review analysis of insurance-claims data, patients who saw a chiropractor for spine pain filled markedly fewer opioid prescriptions than those who did not, a pattern covered in the companion piece on chiropractic care and opioid reduction for spine pain. OPAL explains the mechanism behind that pattern from the other direction: when the drug adds nothing, a care path that leans on movement and hands-on treatment has room to lower opioid exposure without giving up relief.
Does This Mean Opioids Are Useless for Every Kind of Pain?
No, and honesty requires saying so. OPAL tested acute, non-specific low back and neck pain, not cancer pain, surgical pain, or trauma. Opioids remain important tools in those settings. The finding is specific: for the everyday sore or seized-up back and neck that most people get, opioids did not beat a placebo.
It would be a mistake to read OPAL as a blanket verdict on opioids. These drugs have a real and humane role in acute severe pain from surgery, major trauma, and cancer, where the calculus is different and the alternatives are limited. Overreacting to a study by swinging to the opposite extreme is its own error, and it can leave people with genuine severe pain undertreated.
What OPAL narrows in on is one very common scenario: acute, non-specific low back and neck pain, the mechanical kind that most adults will feel at some point. In that specific setting, and against the strongest comparison available, the opioid did not deliver. The earlier evidence base pointed the same direction. A Cochrane systematic review of 15 trials and more than 5,000 patients found that opioids gave only modest short-term relief for chronic low back pain, with trials too short to judge long-term benefit, tolerance, or addiction (Chaparro and colleagues, 2013). OPAL added the missing acute-pain, placebo-controlled piece and found the benefit was not modest, it was absent.
What Do the Guidelines Say Now?
They already moved. The American College of Physicians recommends non-drug care first for back pain, including spinal manipulation, heat, massage, and exercise, and reserves opioids for a last resort after a frank risk discussion. The UK's NICE guidance advises against routine opioid use for back pain and sciatica.
OPAL did not arrive in a vacuum. The major guideline bodies had already been steering away from opioids for back pain, and this trial hardened the case. The American College of Physicians, in its clinical practice guideline for low back pain, recommends that clinicians and patients start with non-drug options: superficial heat, massage, acupuncture, and spinal manipulation for acute pain, and exercise and rehabilitation approaches for chronic pain. Opioids appear only as a last option, to be considered when other treatments have failed and only after an honest conversation about the known risks against realistic benefits (Qaseem and colleagues, 2017).
American College of Physicians guideline, 2017 (Qaseem and colleagues): for acute low back pain, first-line care is nonpharmacologic, including spinal manipulation, superficial heat, and massage. For chronic low back pain, exercise and multidisciplinary rehabilitation come first. Opioids are a last-line option only after other treatments fail and risks are openly discussed.
What this means in plain terms: the official advice for an ordinary hurting back is to try movement and hands-on care before reaching for a pill, and to treat opioids as a distant fallback, not a starting point.
For the full guideline: Qaseem A, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain. Ann Intern Med. 2017;166(7):514-530.
The pattern holds internationally. The UK's National Institute for Health and Care Excellence advises against routine opioid use for low back pain and does not recommend opioids for chronic sciatica, reserving weak opioids for acute back pain only when an anti-inflammatory cannot be used (NICE, 2016, updated 2020). When independent guideline panels on two continents reach the same conclusion, and a placebo-controlled trial then confirms it, the direction of care is clear.
What This Means Clinically
In my practice the takeaway is not to fear medication, it is to lead with the tools that actually match this problem. Acute mechanical back and neck pain responds to reassurance, movement, and hands-on care that restores motion. My job is to get a stiff, guarded person moving comfortably again, then let their own recovery do the rest.
I treat people in Tulsa every week who come in with a back that seized up over the weekend or a neck that locked after a rough night of sleep. Years ago, a fair number of them would have left an urgent care with a few days of opioids. What OPAL tells me, and what I already see in the room, is that the drug was rarely the thing that helped. Time and motion helped. The pill mostly came along for the ride and, for a minority, left a problem behind.
"My goal is to lower the cost of the next movement, not to chase the pain with a stronger chemical."
Here is the mechanical picture. When a spinal segment restricts, the muscles around it guard, movement becomes painful, and a person naturally moves less. Moving less stiffens the joint further and the loop tightens. A targeted adjustment with hands-on soft-tissue work can release that restriction enough to make the next movements tolerable, which is what lets the body's normal recovery take over. I am not claiming an adjustment cures anything or works for everyone. I am saying it addresses the mechanical restriction directly, which is a better match for a mechanical problem than a systemic sedating drug that, in this trial, did nothing measurable. For people whose main issue is a hurting low back, I lay out the full conservative approach on the back pain chiropractor in Tulsa resource.
For Recurring Mechanical Pain, Plan for It
When a back or neck problem is a recurring mechanical pattern rather than a one-time flare, I am honest about the time course. These problems tend to compound with each flare. For a pattern that keeps returning, the responsible approach is ongoing care, roughly once a week for at least twelve weeks after the acute phase settles, then tapering based on whether the symptoms return. That is not a contract and not a package sold up front. It is $40 a visit, you stop whenever you want, and the whole aim is to keep you moving on your own rather than dependent on any treatment, mine included.
Patient Translation: What to Do With a Badly Hurting Back
Stay as active as the pain allows, use heat and simple anti-inflammatories if appropriate for you, and give it time, because most acute back and neck pain improves within weeks. Hands-on care can make moving tolerable sooner. If a clinician offers opioids for ordinary back pain, it is fair to ask about non-drug options first.
If your back or neck just went out, the evidence-based playbook is calmer than it feels in the moment. Keep moving within tolerance rather than going to bed, because prolonged rest stiffens joints and weakens the muscles that support your spine. Gentle walking, heat, and a simple anti-inflammatory if it is safe for you are reasonable first steps. Most acute episodes settle over days to a few weeks on their own. Hands-on care can shorten the miserable early stretch by getting you moving comfortably sooner, which is exactly where most people get stuck.
The point is not that you should refuse every medication or tough it out in silence. The point is that for this kind of pain, the strongest evidence says an opioid is unlikely to add relief and may add risk. So if you are handed a script for ordinary mechanical back pain, it is completely reasonable to ask whether a non-drug path fits your situation first. That is a normal, informed conversation to have with any clinician, and most will welcome it.
When to Skip the Clinic and Go to the ER
Most back and neck pain is mechanical and improves with movement, time, and hands-on care. A few warning signs are not mechanical and need emergency evaluation, not a chiropractor and not a wait-and-see approach. Go to the emergency room, not a clinic, if you have any of these:
Loss of bladder or bowel control, numbness in the saddle area between the legs, or weakness in both legs (possible cauda equina syndrome)
Weakness that is getting worse, numbness that is spreading, or a foot that drags or slaps (progressive nerve damage)
Fever with back pain, recent intravenous drug use, or a weakened immune system (possible spinal infection)
Back or neck pain after a fall, a car accident, or another significant trauma (possible fracture)
New back pain in someone with a history of cancer
A careful evaluation screens for every one of these before any treatment. Honest care means knowing what a spine problem is not, and sending you to the right place fast when it is something else.
Limitations: What This Study Can and Cannot Say
OPAL tested one opioid, oxycodone with naloxone, at up to 20 milligrams of oxycodone per day. It does not speak to every opioid at every dose, though there is no strong reason to expect a different class member would suddenly outperform placebo where this one did not.
The trial studied acute, non-specific low back and neck pain. Its result should not be stretched to cancer pain, post-surgical pain, major trauma, or other severe acute conditions where opioids retain a clear role.
It is a single trial, and single trials can be wrong. That said, OPAL was large, well-designed, triple-blind, and its direction agrees with existing guidelines and the earlier Cochrane evidence, which raises confidence in the finding.
The 6-week pain difference sat right at the edge of significance (p=0.051), so the honest statement is that the opioid was no better than placebo, not that it was meaningfully worse at 6 weeks. The clearer harm signal is the doubled misuse risk at one year.
This commentary concerns elective, non-emergency musculoskeletal pain. It does not apply to the red-flag presentations listed above, which require medical evaluation and are outside the scope of both this trial and this article.
The Bottom Line
For an ordinary badly hurting back or neck, the strongest trial we have found no benefit from opioids over placebo at 6 weeks, and double the misuse risk at one year. The evidence points to non-drug care first: movement, time, and hands-on treatment. You can start that path in Brookside, one $40 visit at a time, with no drug, no contract, and no pressure.
A Non-Drug First Step for a Hurting Back
Walk in to Vanguard Chiropractic in Brookside
If your back or neck went out and you would rather try hands-on care than reach for a pill, walk in and get evaluated. We screen for the red flags first, then work on restoring movement so your own recovery can take over. No referral and no appointment needed.
Vanguard Chiropractic
1334 E 41st St, Brookside, midtown Tulsa, OK 74105
$40 per visit. No contracts. Stop any time.
Walk-in hours: Mon to Fri 10am to 7pm and Sat 10am to 2pm
Veteran-owned. Cash-pay, no insurance hassle.
See Walk-In Details Call (918) 948-7990
Frequently Asked Questions

Do opioids work for back pain?
For ordinary acute low back and neck pain, the best evidence says no better than a placebo. The 2023 OPAL trial (Jones and colleagues) randomly gave 347 patients a real opioid or an identical dummy pill and found the same pain at 6 weeks, plus double the opioid misuse risk at one year. Opioids still matter for severe pain from surgery, trauma, or cancer, but not for the everyday mechanical back or neck.

What did the OPAL trial actually find?
OPAL compared an opioid, oxycodone with naloxone up to 20 mg per day, against a matching placebo in adults with acute low back or neck pain. At 6 weeks, mean pain was 2.78 on the opioid and 2.25 on placebo, a small difference that leaned toward placebo and was not statistically significant. The opioid also gave no edge on function, quality of life, or recovery time, and at one year the opioid group had slightly worse pain and twice the misuse risk.

What should I take instead of opioids for back pain?
Major guidelines put non-drug care first. The American College of Physicians (Qaseem and colleagues, 2017) recommends spinal manipulation, heat, massage, and exercise ahead of medication for back pain. Staying active within tolerance, using heat, and, if appropriate for you, a simple anti-inflammatory are reasonable early steps. Most acute pain settles within weeks. Hands-on care can make movement tolerable sooner. Talk with a clinician about what fits your specific situation.

Are opioids dangerous for short-term use?
Even a short, guideline-style course carries risk. In OPAL, a course of up to 6 weeks for acute back or neck pain was linked to double the rate of opioid misuse a year later, 20 percent versus 10 percent on a validated screening measure, with no pain benefit to offset that risk. That does not mean opioids are never appropriate, but for ordinary mechanical back pain the risk sits on one side of the scale with little benefit on the other.

Does this mean my back pain is not real?
Not at all. Acute back and neck pain is very real, and OPAL never questioned that. The trial only asked whether an opioid relieves that pain better than a placebo, and the answer was no for this kind of pain. Your pain deserves real treatment. The evidence simply points that treatment toward movement, time, and hands-on care rather than a drug that, in this study, added risk without adding relief.

Can a chiropractor help an acute back or neck that just went out?
Often, yes. When a spinal segment restricts and the surrounding muscles guard, movement hurts and people stop moving, which tightens the loop. A hands-on adjustment with soft-tissue work can ease that restriction enough to make movement tolerable again, which is where recovery usually stalls. At Vanguard Chiropractic in Brookside, that is a $40 walk-in visit, no contract, stop any time. We screen for red flags first and refer out when a problem is not mechanical.

Cite This Commentary Forward J. Do opioids actually work for back pain? The Lancet OPAL answer. The Forward Review. 2026;1. https://vanguardchiro.com/research/opioids-back-pain-opal-2026/
Related Reading
Return to The Forward Review Walk-in chiropractor in Tulsa About Dr. Jason Forward, DC
Editorial Disclosure
The Forward Review is editorial commentary, not peer reviewed. Written and medically reviewed by Jason Forward, DC, a licensed chiropractor at Vanguard Chiropractic in Tulsa, Oklahoma. Commentary reflects clinical interpretation and does not represent the views of the OPAL trial authors, The Lancet, the American College of Physicians, NICE, or any institution. Individual results vary.
Conflict of interest: Dr. Forward is a practicing chiropractor whose clinical work includes hands-on conservative care for back and neck pain. No financial relationships with the cited authors or publishers.
Corrections policy: Errors are corrected with a dated correction notice appended to the article. Original text remains accessible via revision history.
Level of evidence: One large placebo-controlled randomised trial (primary), one Cochrane systematic review, and two major clinical practice guidelines. Certainty for the primary finding is moderate to high.
July 7, 2026

Meta-Analysis, 15 RCTs, n=740 Volume 1 · Issue 4 Low Back Pain PRP Injection Outside My Scope

PRP for Low Back Pain in 2026: What a $2,000 Injection Buys You, According to 15 Randomized Trials

Pei and colleagues pooled 15 randomized trials of platelet-rich plasma injection for low back pain in 740 patients and reported large short-term reductions in pain and disability versus controls. Effect sizes are dramatic at one week through six months. Heterogeneity is substantial. Discogenic effects narrow quickly past one month. This commentary is what a Tulsa chiropractor tells the patient who walks in asking whether to spend $1,500 to $3,000 on a PRP injection before they have tried conservative care.

Jason Forward, DC, Vanguard Chiropractic, Tulsa, Oklahoma Published May 11, 2026

Reviewing

Pei X, Liu C, Wang Y, et al. Platelet-rich plasma therapy for low back pain: A comprehensive systematic review and meta-analysis. Journal of Back and Musculoskeletal Rehabilitation. 2026 May 9.

DOI: 10.1177/10538127261448983 · PMID: 42105106

Key Points

Pei and colleagues pooled 15 randomized controlled trials of platelet-rich plasma (PRP) injection for low back pain in 740 patients. Comparators included corticosteroid injections, local anesthetic injections, normal saline placebo, and conservative care alone.
Across all included trials, PRP reduced pain versus controls with a standardized mean difference of -1.32 (95% CI -2.06 to -0.59, p=0.001) and reduced disability with an SMD of -1.04 (95% CI -1.66 to -0.41, p<0.001). The pain benefit was observed at one week, one, two, three, four, and six months.
For the discogenic low back pain subgroup, the pain benefit was statistically significant at the one-month time point but did not hold up at later follow-up. Long-term discogenic effects could not be reliably estimated from the pooled data.
The standardized mean differences are large by chronic pain trial standards. A SMD around -0.5 is conventionally moderate. The pooled estimates here run two to three times that size. The accompanying confidence bands and the authors' own assessment flag substantial heterogeneity across studies.
PRP is an injection therapy delivered by interventional pain physicians or orthopedic specialists. It is not within chiropractic scope of practice. Vanguard Chiropractic does not perform PRP injections and has no financial relationship with any PRP clinic.
Cash price for PRP injection in the US runs roughly $1,500 to $3,000 per injection, almost never covered by insurance. The evidence base supports a short-term pain signal in some patients but does not support PRP as a first-line move for low back pain that has not yet been treated with active conservative care.

Plain Language Summary

Platelet-rich plasma is a procedure where a clinician draws a vial of your blood, spins it in a centrifuge to concentrate the platelets, and injects that concentrate into a painful joint, disc, or soft tissue. The theory is that the growth factors in concentrated platelets help damaged tissue heal. PRP has been around for two decades in sports medicine and orthopedics. The evidence base for low back pain specifically has grown enough in the last few years to support a meta-analysis like this one.

The Pei team pulled together fifteen randomized trials covering 740 patients with low back pain who received either PRP or a control treatment. Across the pool, PRP produced large reductions in pain and disability at most short-term and intermediate time points. For the subset of patients with discogenic low back pain (pain coming from a degenerating intervertebral disc), the benefit narrowed past the first month and the long-term picture could not be reliably mapped from the data.

The honest summary for a patient who is considering PRP: there is a real signal in the short term in some patient subgroups, the effect sizes look bigger than what is typical in chronic pain literature, and the studies disagree with each other enough that you should weight the average lightly. PRP costs $1,500 to $3,000 per injection in cash, is not covered by insurance, and is rarely the right first move before you have given active conservative care a real run. If you have already done conservative care and you are still struggling, a conversation with an interventional pain physician about whether PRP fits your specific case is reasonable. Skipping over conservative care to go straight to the injection is not what the evidence supports.

Why I Am Writing About a Procedure I Do Not Perform

The Forward Review is built around what the published evidence says about conservative care for the conditions I see in my Tulsa walk-in clinic. PRP injection is not conservative care. It is an interventional procedure performed by physicians, not chiropractors. I am writing about it for the same reason I wrote about acupuncture and traditional Chinese medicine: patients ask about it, the marketing around it is loud and expensive, and the honest read of the evidence is different from the marketing read.

PRP for back pain is one of the more visible interventional pain offerings in Tulsa and across the country. Clinics market it as regenerative, drug-free, and minimally invasive. The cash price runs $1,500 to $3,000 per injection, and most patients pay for it out of pocket because insurance carriers classify it as experimental for spinal indications. A patient considering PRP is making a real financial decision, and the marketing materials they will read on the way to that decision are not built around the evidence base. They are built around the sale.

My job in this commentary is to give a calibrated read of what the evidence actually says, what it does not say, and where PRP sits in the broader low back pain treatment hierarchy. I am not an interventional pain physician. I am not in a position to recommend PRP for a specific patient. I am in a position to tell my patients what the published data does and does not support if they ask.

What PRP Is and How It Is Supposed to Work

Platelet-rich plasma is autologous, which means it comes from the patient's own body. The clinician draws a vial of blood, places it in a centrifuge, and separates the components by density. The platelets concentrate in a narrow band, which is collected and injected into the target tissue under imaging guidance. The injection delivers a higher local concentration of platelets and the growth factors they carry than the surrounding tissue would otherwise see.

The mechanistic claim is that these growth factors (transforming growth factor beta, platelet-derived growth factor, vascular endothelial growth factor, and others) participate in tissue repair processes. Concentrating them locally should, in theory, accelerate or improve healing in tissues with poor native blood supply, like tendon, ligament, and intervertebral disc.

For low back pain specifically, the injection target depends on the pain generator. For facet-mediated pain, the target is the facet joint or its capsule. For sacroiliac joint pain, the target is the SI joint. For discogenic pain (pain originating from the disc itself), the target is the intradiscal space. Each target has its own evidence base, its own technical demands, and its own risk profile. Lumping them together in a single meta-analysis is what Pei and colleagues did, and it is part of why the heterogeneity in this paper is so large.

The plausibility of the mechanism is real. Whether the mechanism delivers clinically meaningful relief in a given patient with a given pain generator is a separate question, and that is what the trials are trying to answer.

What This Meta-Analysis Did

Pei and colleagues searched the standard databases for randomized controlled trials comparing PRP injection to a control intervention in adults with low back pain. Fifteen trials met inclusion criteria, totaling 740 patients across the pool. Comparators varied. Some trials used corticosteroid injection as the active comparator. Some used local anesthetic. Some used saline placebo. Some used conservative care alone.

Outcomes were pain (assessed primarily by the Visual Analogue Scale) and disability (assessed primarily by the Oswestry Disability Index). Follow-up time points spanned one week, one month, two months, three months, four months, and six months. The pool was large enough to estimate effects at each time point separately.

The pooled standardized mean differences across all trials and time points came out as follows:

Pooled Pei 2026 Estimates

Outcome	SMD (95% CI)	p-value
Pain (VAS) vs controls, all time points	-1.32 (-2.06 to -0.59)	0.001
Disability (ODI) vs controls, all time points	-1.04 (-1.66 to -0.41)	< 0.001
Pain at 1 week	Significant in favor of PRP	p < 0.05
Pain at 1, 2, 3, 4, and 6 months	Significant in favor of PRP	p < 0.05
Discogenic LBP subgroup at 1 month	Significant in favor of PRP	p < 0.05
Discogenic LBP, later time points	Not reliably estimable	insufficient data

The authors' conclusion: PRP therapy can be considered a viable option for treating low back pain, particularly for short-term to mid-term symptom relief. They flag substantial heterogeneity across the included trials and note that the long-term picture for discogenic low back pain specifically cannot be reliably established from the current evidence.

How To Read These Numbers Without Getting Sold

The headline numbers in this paper are big. A standardized mean difference of -1.32 for pain reduction is, on its face, the kind of effect size that would make any clinician pay attention. Most pain interventions in chronic low back pain trials produce SMDs in the -0.3 to -0.6 range. An SMD past -1.0 is unusual. An SMD past -1.3 with a confidence interval extending past -2.0 is the kind of estimate that should make a careful reader stop and look at the studies feeding the pool.

Three things are worth keeping in mind when reading effect estimates this large in this kind of literature.

The first is heterogeneity. The 95% confidence interval here is -2.06 to -0.59. That spread is enormous. It says the underlying trials disagree with each other about the size of the PRP effect by a factor of three or more. In statistical terms, this is not the kind of estimate that justifies treating the central point estimate as the true effect. It is the kind of estimate that says the true effect probably varies a lot across patient populations, injection targets, PRP preparation protocols, and study designs.

The second is comparator quality. Some of the trials in this pool compared PRP to active treatments like corticosteroid injection. Some compared PRP to saline placebo. Some compared PRP to conservative care. These are very different comparison floors. A 2-point VAS reduction over saline placebo is one kind of finding. A 2-point reduction over an active comparator is a very different finding. Pooling them together compresses the picture and inflates the apparent effect size relative to the actual clinically relevant comparison, which is "PRP versus the next-best alternative the patient could try instead."

The third is blinding and expectancy. PRP procedures are expensive, technically involved, and emotionally weighted for the patient who pays out of pocket. Saline injection controls do not carry the same expectancy load. Open-label or single-blind trials in this kind of high-expectancy procedure tend to over-estimate the specific treatment effect by amplifying the placebo response in the active arm. The Pei pool includes trials of varying blinding rigor, and the pooled estimate inherits that mixed methodology.

None of this means PRP does not work. It means the published pooled effect estimate should be discounted before being read as a personal prediction for a specific patient. The honest read is something like "PRP probably produces a real short-term benefit in some patients with some types of low back pain, the average benefit looks bigger in the literature than it is likely to be in practice, and the long-term picture is not yet mapped."

Where PRP Sits in the Treatment Hierarchy for Low Back Pain

The major clinical guidelines for low back pain do not list PRP injection as a first-line option. The 2017 American College of Physicians guideline placed nonpharmacologic conservative care (spinal manipulation, exercise, heat, acupuncture, mindfulness) at the front of the treatment hierarchy for acute, subacute, and chronic low back pain. The NICE NG59 guideline in the United Kingdom takes a similar position. Neither lists PRP among recommended first-line interventions for nonspecific low back pain. The National Institute of Neurological Disorders and Stroke overview of low back pain also leads with conservative options and reserves injection therapies for refractory cases.

The reasoning is straightforward. Active conservative care is cheaper, has a lower risk profile, has a larger and more mature evidence base, and works on a wider range of pain generators. For most patients with low back pain (including patients with disc-related symptoms), some combination of chiropractic care, physical therapy, structured exercise, and pain education resolves the problem without ever needing an injection. The OPTIMIZE trial in Annals of Internal Medicine showed clearly that starting with active conservative care beat starting with passive medical management at one year. The 2026 Cochrane review on spinal manipulation found small-to-medium effects on pain with no signal of serious adverse events.

PRP sits in the second or third tier of the treatment hierarchy for patients with refractory disc-related pain or sacroiliac pain who have already cycled through conservative care without sufficient benefit. In that context, the Pei meta-analysis is a useful data point. It suggests that for the right patient with the right pain generator and the right clinician, PRP can produce real short-term to mid-term benefit. It does not suggest, and the authors do not claim, that PRP should be the first move on a fresh low back pain complaint.

The Cost Question Nobody at the Injection Clinic Will Walk You Through

Patients in Tulsa asking about PRP almost always come to me after they have already heard the pitch from an interventional pain or regenerative medicine clinic. The pitch is usually clean: a single injection, drug-free, autologous, regenerative. The price is usually quoted as a "package" of one to three injections, with a per-injection number somewhere between $1,500 and $3,000. Insurance is described as "not covering this yet," which obscures the fact that most major US insurers have classified PRP for spinal indications as experimental and are unlikely to begin covering it any time soon.

Run the math against what conservative care delivers. A full course of chiropractic care at Vanguard Chiropractic, at $40 per adjustment with no required package, twelve visits across the first acute-to-stabilization phase, comes to $480. Add another twelve weekly visits in the maintenance phase for patients with recurrent or radicular presentations and you are at $960 for six months of hands-on, evidence-based, guideline-supported care. A single PRP injection sits anywhere from one-and-a-half to three times that total.

Comparative Cash Cost (Tulsa, 2026)

Intervention	Cash price	Insurance coverage	Evidence base for LBP
PRP injection (single)	$1,500 to $3,000	Generally not covered (experimental)	Growing but heterogeneous; not first-line in any major guideline
PRP injection series (1 to 3 over 3 months)	$3,000 to $9,000	Generally not covered	Same as single; series benefit not clearly established
Vanguard Chiropractic, 12 visits	$480	Cash pay model, no claims filed	First-line in ACP, NICE, VA/DoD guidelines
Vanguard Chiropractic, 24 visits over 6 months	$960	Cash pay model, no claims filed	First-line in ACP, NICE, VA/DoD guidelines
Physical therapy block (typical Tulsa cash)	$1,200 to $2,400	Often partially covered	First-line in ACP, NICE, VA/DoD guidelines

None of this is an argument against PRP for the patient who genuinely needs it. The point is that the financial commitment for PRP is meaningful, the evidence base does not support it as a first move, and the patient who has not yet given active conservative care a real run is making a $1,500 to $9,000 decision before they have tested whether a $480 to $960 conservative course would have resolved the problem.

When PRP Probably Is the Right Move

Here is the part where I want to be honest rather than territorial. There are patients for whom PRP is a reasonable, evidence-informed next step. The Pei meta-analysis adds to the case that those patients exist. From the data and from talking to interventional pain colleagues, the patient profile where PRP makes the most sense looks like this.

The patient has had low back pain for more than three months. They have completed a real course of active conservative care: chiropractic, physical therapy, or both, plus structured home exercise, with documented adherence and a fair trial of at least eight to twelve weeks. They are still struggling. Their pain has been worked up by a clinician who has identified a likely pain generator: a specific disc, a facet joint, or a sacroiliac joint. They have had appropriate imaging if indicated and red flags have been ruled out. The proposed PRP target is the identified pain generator, not a vague "low back" injection.

For that patient, the Pei data says PRP can produce short-term to mid-term relief at meaningful magnitudes. The honest framing is that PRP is one of several options at the second-tier intervention level for refractory pain, alongside corticosteroid injection, ablation procedures, and continued intensified conservative care. The choice between those options is a conversation between the patient and an interventional pain or spine physician who knows the patient's case.

What the data does not support is the patient who walks into the regenerative clinic with two weeks of low back pain, no conservative care attempted, no diagnostic work-up, and an offer to "skip the wait" with a $2,500 injection. That is not what the Pei trial pool tested. That is a marketing offer running ahead of the evidence base.

What I Tell My Patients in My $40 Walk-In Clinic

Patients ask me about PRP about twice a month. The conversation goes something like this.

What I do is mechanical care. Spinal manipulation as indicated, soft-tissue work, graded movement loading, brief reframes for fear-avoidance, and a return instruction. I see patients on a walk-in basis, $40 per visit, six days a week, no contracts, no packages, no required pre-pay. For patients with recurrent or radicular presentations, I recommend ongoing weekly care for at least twelve weeks after the acute phase resolves, then a taper. This is not maintenance for its own sake. Each flare of nerve-root irritation compounds tissue and sensitization patterns. Prevention costs less than chasing flares after the fact, both clinically and financially.

For a patient who has not yet tried active conservative care and is asking about PRP, my answer is consistent. Try conservative care first. It is cheaper, lower-risk, evidence-supported by every major clinical guideline, and frequently sufficient. If conservative care does not resolve the problem in eight to twelve weeks of honest effort, and a clinician has identified a specific pain generator that PRP could plausibly target, then a referral to an interventional pain physician for a conversation about PRP, corticosteroid injection, ablation, or other options is a reasonable next step.

For a patient who has already done a real run of conservative care and is asking whether PRP makes sense as their next move, my answer is more open. I do not know their case the way an interventional pain physician would. I can tell them the evidence base supports a real short-term benefit in some patients, the long-term picture is uncertain especially for discogenic pain, the cost is real and is rarely covered by insurance, and that a conversation with a board-certified interventional pain physician who will give an honest read of their candidacy is the right next move. I do not steer them toward or away from the procedure. I tell them what the published data says.

For a patient who has already had PRP and is back in my office because the injection has not held up or because new symptoms have appeared, the conversation is different again. PRP that did not produce sustained benefit does not mean conservative care will not work. It means a different intervention did not work. The mechanical issues that brought the pain in the first place often still respond to conservative care for sciatica or for related disc and nerve presentations, and we start from there.

Mechanism, Honestly Stated

Why might PRP help some patients with low back pain? The biological plausibility runs through growth factors and tissue repair signaling. Concentrated platelets release growth factors that participate in inflammation modulation, cell recruitment, matrix remodeling, and angiogenesis. In tissues with poor native blood supply (intervertebral discs are the canonical example), local delivery of these signals can plausibly nudge a repair process that the tissue would otherwise struggle to mount.

Why might it not help? Pain in chronic low back pain is rarely a clean tissue-damage story. Central sensitization, motor control disruption, fear-avoidance behavior, and deconditioning all contribute to the pain experience independently of tissue state. An intervention that targets local tissue repair does not address the central and behavioral components. For patients whose pain is dominated by mechanical disc-related drivers, the injection may help. For patients whose pain is dominated by central sensitization or fear-avoidance patterns, an injection (any injection) is less likely to produce sustained benefit.

This is part of why active conservative care has such a strong evidence base across heterogeneous patient subtypes. Spinal manipulation, graded loading, and brief cognitive reframes address all four pain-generation channels at once. An injection addresses one. Both can have a role. The order in which they are tried matters.

Limitations and Caveats

Limitations

The 15 trials in the Pei pool used heterogeneous PRP preparation protocols (leukocyte-rich versus leukocyte-poor, single-spin versus double-spin, varying platelet concentration multiples). The pooled estimate assumes a single underlying intervention, which the literature does not actually have. Different PRP preparations may produce different effects, and the meta-analysis cannot disentangle them.

Injection targets varied across studies. Some trials injected the facet joints. Some injected the disc. Some injected the sacroiliac joint. Some injected paraspinal soft tissue. The pooled effect estimate aggregates across these targets despite the underlying pain generators being meaningfully different. Subgroup data is too thin to estimate separate effects reliably for each target.

Comparator quality varied substantially. Some trials used active comparators (corticosteroid injection). Some used saline placebo. Some used conservative care alone. The pooled estimate is inflated relative to the clinically relevant question, which is PRP versus the next-best alternative.

Blinding was inconsistent. PRP procedures carry high expectancy effects given the cost, technical complexity, and patient time investment. Single-blind or open-label trials likely over-estimate the specific PRP effect by amplifying placebo response in the active arm.

The discogenic low back pain subgroup is where mechanistic plausibility for PRP is strongest. The Pei pool found a significant pain benefit in this subgroup at one month, but the benefit did not hold reliably at later time points and the long-term picture could not be estimated. This is the population where PRP marketing is most aggressive, and it is also the population where the published evidence is most uncertain past 30 days.

Adverse event reporting in the abstract is limited. PRP is generally considered low-risk when performed by qualified clinicians, but the full safety picture from the included trials is not summarized in the meta-analysis abstract. Patients considering PRP should review the risk profile with the performing physician, not extrapolate safety conclusions from a pooled effect estimate.

PRP is not within chiropractic scope of practice in Oklahoma. Vanguard Chiropractic does not perform PRP injections, does not have a financial relationship with any PRP clinic, and does not refer patients to specific PRP providers. This commentary is editorial analysis of published research, not a referral or endorsement.

The Tulsa Practical Read

For a patient in Brookside or midtown Tulsa weighing whether to spend $1,500 to $3,000 on a PRP injection, the practical filter looks like this. Have you tried active conservative care yet? A real course of chiropractic, physical therapy, or both, with structured home exercise, for eight to twelve weeks of honest effort? If the answer is no, that is the next move. Conservative care is cheaper, has a stronger evidence base for first-line use, has a lower risk profile, and frequently resolves the problem without ever needing an injection.

If you have already done that and you are still struggling, the conversation shifts. At that point, an interventional pain physician who can identify your specific pain generator and walk you through the options (PRP, corticosteroid, ablation, intensified conservative care, surgical consult if indicated) is the right next stop. The Pei meta-analysis adds to the case that PRP belongs in that conversation for the right patient. It does not belong as the first move.

For my walk-in patients, the practical answer is the same one I give for every condition. Show up. $40 per visit, six days a week, no appointment required, no contracts. We work the mechanical pieces. If you have a problem that I cannot resolve, I will tell you, and I will point you toward the next provider who is best positioned to help. PRP is one of those next-provider options for the right patient. It is not a replacement for the front door of conservative care that the guideline literature has been pointing at for a decade.

The Bottom Line

Pei and colleagues pooled 15 randomized trials of PRP for low back pain in 740 patients and found large short-term to mid-term reductions in pain and disability versus controls. The effect sizes are bigger than typical chronic pain literature. Heterogeneity is substantial. Long-term discogenic effects are not reliably mapped. PRP runs $1,500 to $3,000 per injection in cash, is rarely covered by insurance, and is not first-line in any major clinical guideline for low back pain. The right read is that PRP can help some patients with refractory pain who have already cycled through conservative care without sufficient benefit. It is not the first move on a fresh low back pain complaint, and the patient who has not yet tried active conservative care is making a $1,500 to $9,000 decision before they have tested a $480 to $960 alternative that the guideline literature actually recommends first.

Cite This Commentary Forward J. PRP for low back pain in 2026: what a $2,000 injection buys you, according to 15 randomized trials. The Forward Review. 2026;1(4). https://vanguardchiro.com/research/platelet-rich-plasma-low-back-pain-meta-pei-2026/

Editorial Disclosure

The Forward Review is editorial commentary, not peer reviewed. Written by Jason Forward, DC, a licensed chiropractor at Vanguard Chiropractic in Tulsa, Oklahoma. Commentary reflects clinical interpretation of published research and does not represent the views of the original study authors, the journal, or any institution.

Scope of practice note: Platelet-rich plasma injection is not within chiropractic scope of practice in Oklahoma. Vanguard Chiropractic does not perform PRP injections and has no financial relationship with any PRP, regenerative medicine, or interventional pain clinic. This commentary is editorial analysis of published research, not a referral, endorsement, or recommendation for or against any specific provider or facility. Patients considering PRP should consult a board-certified interventional pain physician, orthopedic specialist, or physiatrist.

Conflict of interest: Dr. Forward is a practicing chiropractor whose clinical work includes spinal manipulation as part of a multimodal approach to musculoskeletal care. No financial relationships with the cited authors, the journal, or any party to this work. No referral relationships with PRP providers in the Tulsa market or elsewhere.

Clinical safety: This commentary discusses published research and does not constitute individual treatment prescription. Patients with new or worsening back pain should be evaluated by a qualified clinician. Red flags including unexplained weight loss, fever, progressive neurological deficit, bowel or bladder changes, or saddle anesthesia require urgent medical evaluation.

Corrections policy: Errors are corrected with a dated correction notice appended to the article. Original text remains accessible via revision history.

Level of evidence: Systematic review and meta-analysis of randomized controlled trials, 15 trials, n=740 patients. Published in the Journal of Back and Musculoskeletal Rehabilitation, May 9, 2026.

May 11, 2026

Home›The Forward Review›Volume 1, Issue 1
The Forward Review Live Commentary Vol. I · Issue 1 · April 2026
Systematic Review with Meta-Analysis Volume 1 · Issue 1 Opioid Use Spine Pain
Six Million Records, 64 Percent Lower Opioid Odds, and Why GRADE Still Says Very Low
Emary and a 16-author team pooled 20 studies on chiropractic care and opioid use for noncancer spine pain. The combined dataset, 6,036,058 patients, is the largest yet brought to bear on this question. The headline number, 64 percent reduction in the odds of receiving an opioid prescription, lands inside a body of work that GRADE rates very low certainty across the board. Both facts have to travel together.
Jason Forward, DC, Vanguard Chiropractic, Tulsa, Oklahoma Published April 29, 2026
Reviewing
Emary PC, Corcoran KL, Coleman BC, et al. Impact of chiropractic care on opioid use for noncancer spine pain: systematic review and meta-analysis. Pain Reports. 2026 Feb;11(1):e1374.
DOI: 10.1097/PR9.0000000000001374 · PMID: 41404361
Key Points
Emary and colleagues conducted a systematic review with meta-analysis of chiropractic care and opioid use for adults with noncancer spine pain. Twenty studies met inclusion. Pooled sample 6,036,058 patients, the largest dataset assembled on this question.
The pooled odds ratio for receiving an opioid prescription among patients who saw a chiropractor was 0.36 (approximately a 64 percent reduction in odds) compared with patients who did not. The effect held across cohort, claims, and registry designs.
GRADE certainty of evidence across the synthesis: very low. The body of evidence is dominated by observational designs with high baseline risk of confounding by indication and selection.
Findings align with the U.S. Centers for Disease Control and Prevention 2022 Clinical Practice Guideline, which recommends nonpharmacologic approaches as first-line care for many forms of chronic noncancer pain. The Emary review adds population-scale evidence consistent with that recommendation while not establishing causation.
The clinical signal is plausible, large, and policy-relevant. It is not yet causal evidence. The honest framing for both clinicians and policymakers is: chiropractic utilization is associated with substantially lower opioid prescribing, with very low certainty about the size of the true causal effect.
This commentary connects the Emary 2026 finding to the broader manual-therapy evidence base, including the Cochrane de Zoete 2026 spinal manipulation review and the JAMA Bronfort 2026 PACBACK trial.
Plain Language Summary
Spine pain is one of the most common reasons adults end up on opioid medications in the United States. Researchers pooled 20 studies covering more than six million patients to ask a single question. Among adults with noncancer spine pain, do those who see a chiropractor receive opioid prescriptions less often than those who do not?
The pooled answer was a roughly 64 percent reduction in the odds of receiving an opioid prescription among patients who used chiropractic care. That is a large association, and the dataset behind it is the biggest ever brought to this question.
The catch is that nearly all of the included studies were observational. Patients who choose chiropractic care differ from patients who do not, in ways that affect opioid prescribing on their own. The certainty of the evidence, graded with the standard GRADE framework, came out as very low. The signal is real and consistent. The size of the true causal effect is not yet established.
Why This Paper Matters
The U.S. opioid crisis remains the dominant pain-policy story of the last fifteen years. Provisional Centers for Disease Control and Prevention data continue to put annual overdose deaths at over 80,000, with prescription opioids contributing as both a primary driver and a known risk factor for transition to illicit use. Spine pain (low back, neck, and mid-back complaints) is the single most common pain indication for which opioids have historically been prescribed. The CDC Clinical Practice Guideline for Prescribing Opioids for Pain (Dowell et al., 2022, MMWR) recommends maximizing nonpharmacologic and nonopioid approaches before reaching for an opioid prescription for most chronic pain conditions.
The unanswered question for both clinicians and policymakers has been the size of the population-scale effect of nonpharmacologic care on actual prescribing patterns. Several earlier studies (Whedon et al., 2018, JMPT; Corcoran et al., 2020) found that patients who use chiropractic care receive opioids at lower rates than matched patients who do not. The samples were measured in tens of thousands at most, and the systematic-review picture of the question stayed thin.
Emary and colleagues set out to fix that gap by pooling everything that has been published. The combined dataset, 6,036,058 patients, is the largest synthesis on this question to date. Whether it definitively answers the question is a separate matter from whether it is the most relevant policy-grade evidence currently available. It is both the largest and the most cautious read of the field.
What the Study Did
The review was conducted by a team led by Peter C. Emary at the Michael G. DeGroote Institute for Pain Research and Care at McMaster University, with co-authors spanning the Veterans Affairs Connecticut Healthcare System, Yale, and other chiropractic outcomes research groups. The authorship roster carries weight in chiropractic outcomes research and in the broader spine-pain evidence space.
The protocol was registered with PROSPERO before data extraction. The team searched MEDLINE, Embase, CINAHL, the Cochrane Central Register of Controlled Trials, ICL, and Web of Science. Eligible studies were randomized controlled trials, prospective cohort studies, retrospective cohort studies, and large claims- or registry-based analyses comparing opioid use outcomes between adults with noncancer spine pain who received chiropractic care and those who did not.
Twenty studies met inclusion. The vast majority were observational, drawing on insurance claims databases, military health system data, Medicare or Medicaid populations, and integrated health-system electronic health records. Pooling was performed using random-effects meta-analysis. Heterogeneity was characterized with the I-squared statistic. Risk of bias was assessed using design-appropriate tools (Cochrane RoB-2 for the small number of randomized trials, ROBINS-I for nonrandomized comparative designs). Certainty of evidence across outcomes was rated using the GRADE framework. Reporting followed PRISMA 2020.
The methodological scaffolding is appropriate. The review is doing what a contemporary systematic review of observational pain-care data should do, with explicit recognition of the limits of the underlying evidence base.
What the Study Found
The headline result is the pooled odds ratio for receiving an opioid prescription. Patients who used chiropractic care for noncancer spine pain had pooled odds of receiving an opioid prescription of approximately 0.36 compared with comparator patients who did not, with a corresponding interpretation of roughly a 64 percent reduction in odds. The point estimate was reasonably consistent across geographic settings, payer types, and design subtypes within the observational pool.
The absolute-numbers picture follows the headline. With more than six million patients pooled, the effect is not a noisy estimate from underpowered studies. Heterogeneity was meaningful, as expected when combining studies with different opioid-prescribing baselines, different chiropractic-utilization definitions, and different time horizons. The direction of the effect did not flip across studies. No included study found that chiropractic care was associated with higher opioid use.
Secondary outcomes (where reported) followed the same direction. Lower morphine milligram equivalent doses among those who did receive opioids. Shorter durations of opioid therapy. Lower rates of long-term opioid use (defined variably across studies as 60 to 90 days or more of continuous prescribing). Each of these secondary findings rests on smaller subsets of the pooled data and carries wider confidence intervals.
The certainty rating, applied across every outcome the review evaluated, came out as very low per GRADE. That is the rating any honest reader has to carry into the interpretation. A very-low rating does not mean the finding is wrong. It means the design of the available evidence does not support strong claims about the size of the causal effect, and that future high-quality research could meaningfully shift the estimate.
Mechanism and Clinical Context
Why would chiropractic care be associated with lower opioid prescribing for noncancer spine pain? The mechanistic answer is both simple and partial.
For mechanical low back pain, chiropractic care delivers spinal manipulation, soft-tissue work, mobilization, and graded loading that act on the local mechanical contributors to pain (joint restriction, surrounding muscle tone, movement patterning). The Cochrane de Zoete 2026 update pooled 76 RCTs on spinal manipulation for chronic low back pain and found small-to-medium effects on pain at low certainty, with no signal of serious adverse events. The Bronfort 2026 PACBACK trial in JAMA tested manipulation against medical care and against biopsychosocial self-management, finding that biopsychosocial self-management beat usual medical care while manipulation alone did not consistently outperform medical care on the primary outcome. The clinical signal across this body of work is modest pain benefit, similar to or better than non-opioid medical management.
Mechanistically, when patients reach pain levels they consider tolerable through non-pharmacological means, the demand for opioid prescriptions drops. The intervention does not have to "cure" the spine pain to reduce opioid demand. It has to reduce pain and improve function enough that the patient and clinician do not escalate to opioids as the next step.
There is also a referral-pathway story. Patients who present to a chiropractor first are entering a care pathway that does not have opioid prescribing as a default option. A patient who presents to a primary-care office or an urgent care for the same complaint is in a pathway where an opioid is on the menu. The Emary review cannot separate the pain-relief mechanism from the pathway-of-care mechanism. Both probably contribute to the observed association.
None of this proves causation. It explains why an association of this size would be biologically and structurally plausible. Mechanism plausibility is necessary, not sufficient, for causal claims.
Limitations and Caveats
The very-low GRADE rating is not a footnote. It is the central honest reading of this paper. Several specific issues drive that rating, and they are worth naming.
Limitations
Confounding by indication is the largest threat. Patients who choose to see a chiropractor differ systematically from patients who do not, in ways that influence opioid prescribing independent of any treatment effect. Self-selected chiropractic users tend to have lower baseline opioid use, lower comorbid mental-health-condition prevalence, higher socioeconomic status, and stronger health-seeking patterns. Statistical adjustment in the included studies addressed measured confounders. Unmeasured confounding cannot be adjusted away.
Selection bias compounds the confounding. Insurance plans that cover chiropractic care attract a different patient population than plans that do not. Geographic regions with high chiropractor density attract a different population than regions without. The pooled estimate combines studies that handled this issue with different degrees of rigor.
Outcome heterogeneity is meaningful. Some included studies measured "any opioid prescription within 12 months." Others measured "long-term opioid therapy" or "morphine milligram equivalent dose." The studies were combined into the pooled odds ratio because the direction of effect aligned, not because the outcomes were identical. The effect size estimate carries that imprecision.
Publication and language bias remain plausible. Chiropractic outcomes research has a built-in incentive structure to publish favorable findings. Whether unpublished null or unfavorable results exist in unpublished theses, internal payer analyses, or non-English literature is unknown. The included studies all reached the published English-language literature, which is itself a filter.
The randomized evidence inside the pool is small. The vast majority of the 6 million pooled patients come from observational claims and registry data. The randomized comparisons that exist are not powered to estimate opioid-prescribing differences with precision.
The review cannot disentangle the pain-relief mechanism from the care-pathway mechanism. Patients who present to a chiropractor first receive a different set of clinical defaults than patients who present to other clinicians first. Both could plausibly drive the observed association. The data does not separate them.
The methodological problems above are not unique to this review. They are characteristic of the entire body of population-scale evidence on nonpharmacologic care and opioid prescribing. The Emary team's contribution is to pool the largest dataset ever assembled on this question and to honestly grade the certainty as very low. That second part matters as much as the first.
What I Take From This for Practice
I see noncancer spine pain every day in my Tulsa walk-in clinic. The typical case is a working-age adult presenting with mechanical low back pain, mid-back tightness, or cervicogenic headache, often after weeks of self-management failed and before they have considered going to a primary care provider. The clinical question I am most often answering is not "should this patient get an opioid." It is "what is the next reasonable step in this patient's care."
The Emary review does not change my fundamental approach to that patient. What it does is sharpen the language I can use when patients ask about the bigger pain-and-medication picture. I now have a defensible citation for the statement that chiropractic utilization is associated with substantially lower opioid prescribing in adults with noncancer spine pain. The honest qualifier travels with the citation: this association is consistent across a six-million-patient dataset, with very low certainty about the size of the true causal effect.
For clinical practice, I take three concrete things from this paper.
One: The pathway-of-care framing is worth taking seriously.
If part of the observed association is driven by patients entering a care pathway without opioid-as-default, then the public-health value of widening access to nonpharmacologic care is partly about which pathway patients enter, not just about which intervention they receive once they are in it. That has implications beyond what individual chiropractors do in their own clinics. It is a referral-architecture and insurance-design question.
Two: The conservative-first care pathway has consistent evidence behind it, even when each individual piece is graded low or very low.
Cochrane gave spinal manipulation for chronic LBP a small-to-medium effect at low certainty (de Zoete 2026). PACBACK showed biopsychosocial self-management beat usual medical care at the trial level (Bronfort 2026). The Emary review now adds population-scale evidence consistent with both. None of these papers alone is decisive. Read together, they triangulate the same direction. That is how cumulative evidence builds in pain research, even when the GRADE ratings stay modest.
Three: The very-low certainty rating cuts against overclaiming, but it does not cut against the recommendation.
A patient or a referring clinician who asks "is the evidence strong" should hear "no, the certainty is very low." A patient or referring clinician who asks "is the evidence consistent" should hear "yes, the direction of effect across 6 million patient records is consistent." Both statements are true. Conflating them is the failure mode the GRADE framework was built to prevent.
The CDC Clinical Practice Guideline already recommends nonpharmacologic approaches as first-line care for many forms of chronic noncancer pain. The Emary review is consistent with that recommendation. It does not constitute the high-certainty causal evidence that would let the guideline upgrade the recommendation strength. A different study design, ideally large pragmatic trials embedded in real-world health systems, would be required for that.
What I tell patients in my Tulsa walk-in clinic when they ask about the medication picture has not fundamentally changed. Conservative care first, with a clear plan for when to escalate or refer. Imaging when red flags are present. Honest discussion of what chiropractic does well (mechanical pain modulation, function restoration, return to load tolerance) and what it does not do well (centrally-mediated pain, certain neuropathic patterns, conditions outside scope of practice). The Emary review supports that conversation. It does not change its content.
What the Review Does Not Resolve
The review does not establish that chiropractic care causes lower opioid use. The data is not designed to support that claim. A pragmatic randomized trial of "first-line chiropractic referral" versus "usual care" with opioid prescribing as the primary outcome would. No such trial currently exists at the scale this question requires.
The review does not separate by spine-pain subtype. Acute low back pain, chronic low back pain, neck pain, mid-back pain, and radicular pain are all mechanically and prognostically distinct. The pooled estimate treats noncancer spine pain as a single category. Subgroup analysis by pain duration and anatomical region would clarify which patient subsets show the largest signal.
The review does not test the chiropractic-utilization-intensity relationship. Whether one chiropractic visit is associated with the same odds reduction as a course of ten visits is a separate question that the pooled data does not answer cleanly.
The review does not adjudicate which specific chiropractic interventions drive the association. Spinal manipulation, manual therapy, exercise prescription, education, and lifestyle counseling are all delivered in chiropractic care, in varying combinations. The Emary pool treats "chiropractic care" as the unit of comparison. It does not unpack that unit.
None of these unresolved questions undermine the headline. They define the next research agenda.
The Bottom Line
Twenty studies, more than six million patients, pooled odds of receiving an opioid prescription approximately 64 percent lower among patients with noncancer spine pain who used chiropractic care. The largest synthesis ever brought to this question. The certainty of evidence, graded by the standard framework, is very low. The honest read for clinicians and policymakers is that chiropractic utilization is consistently associated with substantially lower opioid prescribing, with appropriate humility about the size of the causal effect. The direction of the field is settled. The magnitude is not.
Cite This Commentary Forward J. Six million records, 64 percent lower opioid odds, and why GRADE still says very low. The Forward Review. 2026;1(1). https://vanguardchiro.com/research/chiropractic-opioid-reduction-spine-pain-emary-2026/
Read More From This Issue
Cochrane Verdict on Spinal Manipulation for Chronic LBP (de Zoete et al. 2026) PACBACK in JAMA: 1,000 Patients, Four Treatment Arms (Bronfort et al. 2026) Spinal Manipulation Research Waste (Elliott et al. 2026 TSA) Chiropractic for Military Low Back Pain: Mediators of Effect Non-Surgical Lumbar Stenosis: 5-Year Clinical Course (McAuliffe et al. 2026) Forty-Seven Trials of TMD Patient Education (Ferland et al. 2026) Return to Volume 1, Issue 1 Clinical resource: Walk-in chiropractor in Tulsa
Editorial Disclosure
The Forward Review is editorial commentary, not peer reviewed. Written by Jason Forward, DC, a licensed chiropractor at Vanguard Chiropractic in Tulsa, Oklahoma. Commentary reflects clinical interpretation and does not represent the views of the original study authors, the journal Pain Reports, the International Association for the Study of Pain, or any institution.
Conflict of interest: Dr. Forward is a practicing chiropractor whose clinical work includes care for adults with noncancer spine pain. No financial relationships with the cited authors, the publisher, or any party to this work.
Scope of practice note: Chiropractors do not prescribe opioids. Discussion of opioid prescribing in this commentary refers to prescribing patterns by other clinicians within the broader pain-care system, not to chiropractic clinical decision-making.
Corrections policy: Errors are corrected with a dated correction notice appended to the article. Original text remains accessible via revision history.
Level of evidence: Systematic Review with Meta-Analysis (20 studies, n=6,036,058). GRADE certainty: very low.
April 29, 2026
Home›The Forward Review›Volume 1, Issue 1 · Health Policy
The Forward Review Health Policy Commentary Vol. I · Issue 1 · April 2026
Cochrane Overview · Health Policy Volume 1 · Issue 1 Healthcare Design Rehabilitation Systems
How Rehabilitation Care Is Designed, and What Cochrane Found When It Mapped the Evidence
Del Furia, Negrini, and a 25-author team led by the WHO Rehabilitation Programme produced a Cochrane overview of how rehabilitation services are organized, who delivers them, and where they are provided. Of 25 included systematic reviews, only 5 contributed reliable evidence, and most evidence centered on a single topic (telerehabilitation). The structural finding is not in the data. It is in the gaps.
Jason Forward, DC, Vanguard Chiropractic, Tulsa, Oklahoma Published April 25, 2026
Health policy commentary. This is the first in a new editorial track on The Forward Review covering structural healthcare research that intersects with musculoskeletal care. Tone is structural critique, not advocacy. The frame is what the evidence shows about how care is organized, who pays for it, and what those structures produce. For the philosophical context, see The Declaration on Healthcare System Incentives. Nothing here constitutes medical advice.
Reviewing
Del Furia MJ, Minozzi S, Battel I, Cordani C, Arienti C, et al. Delivery arrangements for rehabilitation services in health systems: an overview of systematic reviews. Cochrane Database of Systematic Reviews. 2026;4(4):CD016348.
DOI: 10.1002/14651858.CD016348 · PMID: 42011808
Key Points
This is one of four parallel Cochrane overviews produced jointly by Cochrane Rehabilitation and the World Health Organization Rehabilitation Programme. The four overviews map the evidence on the four pillars of health policy and systems research (HPSR) defined by the Cochrane Effective Practice and Organisation of Care (EPOC) taxonomy: delivery, financial, governance arrangements, and implementation strategies.
This particular overview covers DELIVERY ARRANGEMENTS, defined by EPOC as "how health services are organized and delivered, including who provides care, how care is coordinated and managed, and where services are provided."
25 systematic reviews were screened. Three overlapped. 17 of the 25 had LOW or CRITICALLY LOW AMSTAR 2 confidence ratings. Only 5 reviews contributed to synthesis. Only 3 of those had moderate to high confidence on outcomes of interest.
Almost all reliable evidence focused on TELEREHABILITATION, plus one review of advanced practice physiotherapy (APP) for spinal pain.
Across the available evidence, the consistent finding is "little to no effect." Telerehabilitation vs usual care: little or no effect on quality of life, ADL, depression, mobility. Advanced practice physiotherapy vs usual care for spinal pain: little to no difference. Telerehabilitation vs in-person: little to no difference.
What is conspicuously ABSENT: equity outcomes, quality-of-care outcomes, adverse events, and four of the five EPOC delivery-arrangement subcategories. The overview reveals an evidence base that has been built where it is easiest to build, not where it would be most useful.
Plain Language Summary
If you want to know whether telerehabilitation works as well as in-person rehabilitation, this paper has an answer: probably about the same, in the populations studied. If you want to know how rehabilitation care should be organized at the system level, who should provide it, where it should be delivered, and whether different arrangements affect cost, equity, or access, this paper has very little to tell you. Not because the team did not look. Because the underlying evidence does not exist.
The Cochrane Collaboration teamed up with the World Health Organization to map the evidence on rehabilitation system design. Of 25 systematic reviews they found, two-thirds were of low quality. Of the remainder, most studied one specific question (does telehealth work as well as in-person?) and almost none addressed the bigger structural questions a policy maker would ask.
The clinical takeaway is small. The structural takeaway is large. The literature on how rehabilitation gets organized has been built around what is measurable and fundable, not around what would help us answer how care should be designed.
The Question
Healthcare policy and systems research (HPSR) is the discipline that asks how care is organized, financed, governed, and implemented at the system level. The Cochrane Effective Practice and Organisation of Care (EPOC) Group is the methodological home for this work within Cochrane. EPOC's taxonomy divides HPSR into four pillars: delivery arrangements (how care is organized), financial arrangements (how care is paid for), governance arrangements (who decides what care happens), and implementation strategies (how new approaches enter practice).
In 2026, Cochrane Rehabilitation and the WHO Rehabilitation 2030 Programme co-produced four overviews, one for each EPOC pillar, focused on rehabilitation specifically. The Del Furia paper covers the first pillar: delivery arrangements. Sibling papers on financial, governance, and implementation are published or forthcoming.
The clinical motivation is obvious. Rehabilitation is one of the most variable healthcare services in the world. Who provides it (PT, OT, physiatrist, chiropractor, exercise physiologist, primary care) varies by country, region, and payer. Where it is provided (hospital, outpatient clinic, home, telehealth, community center) varies likewise. How it is coordinated (single-provider vs multidisciplinary, integrated vs fragmented) varies further still. Recommending better systems requires evidence on what different arrangements produce.
What They Found
The team searched Epistemonikos and EPOC databases for systematic reviews of randomized and non-randomized intervention studies evaluating delivery-arrangement effects in rehabilitation. They used AMSTAR 2 to appraise the included reviews. The numbers are sobering.
25 reviews met inclusion criteria. 3 of those overlapped, leaving 22 unique. 17 of the 22 had LOW or CRITICALLY LOW confidence on AMSTAR 2. That is the methodological floor: a meta-analysis can only be as trustworthy as the systematic reviews it pools, and three-quarters of the reviews available were not strong enough to anchor confident conclusions.
Five reviews contributed to the synthesis. Three of those reached moderate to high confidence on outcomes of interest. Their findings:
Advanced practice physiotherapy (APP) for adults with spinal pain. One review pooled 2 studies and 225 participants. APP models compared with usual care produced little to no difference on the Pain Disability Index or EuroQol-5D after the intervention (SMD 0.05, 95% CI -0.32 to 0.42, low certainty). In other words: changing who delivers care, from a generalist to an advanced-practice provider, did not move the outcomes patients care about.
Telerehabilitation for older adults. One review pooled 3 studies and 179 participants comparing telerehabilitation with usual care. After 7 to 20 weeks, little or no effect on quality of life (SMD -0.09, low certainty). Mobility, strength, and balance estimates were directionally favorable to telerehab but very low certainty with confidence intervals crossing zero.
Telerehabilitation for stroke survivors. One review pooled multiple studies (up to 1,145 participants for some outcomes). Telerehabilitation vs usual care: probably little or no effect on independence in ADL, self-reported quality of life, or depression at 6 to 24 weeks (moderate certainty). Compared with in-person rehabilitation, telerehabilitation produced little to no difference on ADL, balance, or upper limb function.
The pattern is consistent: where the evidence is strong enough to draw conclusions, the effect of these specific delivery arrangements on patient outcomes is small. Telehealth, where it has been studied, looks roughly comparable to in-person care. Advanced-practice models of care delivery look roughly comparable to usual care.
The Bigger Finding Is in the Gaps
The clinical findings above are a small part of the story. The structural finding is more important.
EPOC defines five subcategories of delivery arrangements: who provides care, what care is provided, where care is provided, how care is coordinated, and how care is delivered with information and communication technology. The Del Furia overview was able to find reliable evidence in only TWO of the five subcategories. Most of that evidence was concentrated on a single topic (telerehabilitation, an ICT subcategory). The other three subcategories (what care is provided, where, how it is coordinated) were essentially blank.
Equity-related outcomes were absent from the included reviews. Quality of care, adverse events, and the team's preferred system-level outcomes were rarely reported. The reviews focused on patient-level effects (does the intervention help an individual?) rather than system-level effects (does the arrangement help a population, an underserved community, a healthcare budget?).
This is the structural critique. The evidence base for how rehabilitation should be organized has been built around what is measurable in conventional RCTs (does telehealth produce the same disability score as in-person?), not around what would help a policymaker design a better system (which arrangements produce equitable access? which produce affordability? which produce quality variation?). The questions that an EPOC overview is designed to answer have not been studied at the scale or with the rigor that those questions deserve.
Why the Evidence Got Built the Way It Did
The pattern visible in the Del Furia paper is consistent with a structural reality I have written about elsewhere. Research follows funding. Funding follows what is measurable, scalable, and answerable in a 3-to-5-year grant cycle. Telehealth-vs-in-person is answerable in that timeframe. "Does our healthcare system produce equitable rehabilitation access?" is not. Quality-of-care variation across arrangements requires multi-year observational research, large administrative datasets, and political will to act on the findings. RCT-graded evidence cannot be expected to fill this gap because the question is not RCT-shaped.
The Del Furia team explicitly notes this. Their concluding recommendation: "Future Cochrane overviews in HPSR should consider a broader range of study designs, such as observational, qualitative, and mixed-design evidence, to better capture evidence on delivery arrangements in rehabilitation."
That recommendation is correct. It also requires a methodological shift that the field has resisted for decades. Observational evidence is harder to pool. Qualitative evidence is harder to summarize. The Cochrane infrastructure is built around RCT meta-analysis. Asking it to absorb mixed-design evidence is asking for a different kind of synthesis. It is the right ask. It will take time.
What This Means for Chiropractic Practice and Patients
Three implications I would flag, with varying confidence levels.
First, the absence of strong delivery-arrangement evidence does NOT mean delivery arrangements do not matter. It means they have been studied less rigorously than the clinical effectiveness questions covered in other commentaries this issue (the Cochrane SMT review and the PACBACK trial). The field has invested heavily in "does this treatment work" and lightly in "does this care arrangement work." The investment imbalance has consequences for what is known and for what gets reformed.
Second, the cash-pay walk-in chiropractic model that Vanguard Chiropractic operates is not represented in any of the included reviews. The Del Furia paper considers arrangements within insurance-billing rehabilitation systems. Cash-pay direct-care models exist outside that frame. Clinics like mine do not appear in the literature because the literature has not studied this arrangement. That is a research gap, not a policy verdict.
Third, telehealth has been studied more than other delivery arrangements largely because telehealth standardizes well. Standardization makes RCTs feasible. Other arrangements (community-based care, integrative-medicine clinics, primary-care-embedded chiropractic, FQHC integration models) standardize less well, so they get studied less. The result is that telehealth dominates the evidence base for delivery arrangements not because it is the most clinically interesting, but because it is the easiest to study under conventional methods.
Connecting to the Declaration
This commentary is the first health-policy article in The Forward Review. It connects directly to Article I (On Design) of the Declaration on Healthcare System Incentives. The Declaration argues that healthcare structure is shaped by incentive design rather than by deliberate planning, and that the system optimizes for what is reimbursable, measurable, and scalable rather than for what is most useful to patients or populations. The Del Furia paper is, in effect, the empirical receipts for that argument as it applies to rehabilitation. The evidence base that exists is the evidence base that grant funders, RCT methodology, and Cochrane publication norms produced. The evidence base that does NOT exist (equity, quality of care, system-level outcomes, four of five EPOC subcategories) is the evidence base that funders, methods, and norms did not produce.
This is not corruption. The Declaration is careful about this point. It is structural gravity. Evidence accumulates where the inputs accumulate. The Cochrane and WHO teams writing this paper are working in good faith to map what exists. What exists has been shaped by decades of incentive design that prioritized treatment effectiveness over arrangement effectiveness.
Limitations
This is an overview of systematic reviews, not a primary effectiveness study. The reliability of the conclusions depends on the underlying systematic reviews, 17 of 25 of which had low or critically low AMSTAR 2 confidence.
Most reliable evidence concentrated on telerehabilitation and on a handful of populations (older adults, stroke survivors, adult spinal pain). Generalization to other rehabilitation populations or other delivery arrangements is limited.
The included evidence is dominated by high-income country settings. Low- and middle-income country evidence is thin or absent. Generalization globally is correspondingly limited.
The conflict-of-interest disclosures are extensive. Multiple authors are WHO-connected (Atkinson-Graham, Duttine, Mudau, De Groote, etc.) and several authors hold advocacy roles for the WHO Rehabilitation 2030 initiative. The disclosures are transparent and consistent with standard practice in WHO-collaboration research, but readers should know.
One author (NB Bakaa) is a chiropractor in private practice. One author (MA Atkinson-Graham) had recent employment with World Spine Care, a chiropractic-affiliated charity. The chiropractic perspective is represented but not dominant.
The overview's own recommendation, that future syntheses should incorporate observational and qualitative evidence, implicitly acknowledges that the current Cochrane methodology may not be the best fit for the questions a healthcare system needs answered.
The Bottom Line
Cochrane and the WHO mapped the evidence on how rehabilitation services are organized, and the map mostly shows where the evidence does NOT exist. Where it does exist, the differences between delivery arrangements appear small. The structural finding is that the evidence base has been built around what is measurable in RCTs, not around what would help a policymaker design a better system. This is the empirical face of the Declaration's claim that healthcare structure follows incentive design rather than deliberate planning.
Cite This Commentary Forward J. How rehabilitation care is designed, and what Cochrane found when it mapped the evidence. The Forward Review. 2026;1(1). https://vanguardchiro.com/research/cochrane-epoc-rehabilitation-delivery-arrangements-delfuria-2026/
Read More From This Issue
Editorial Foundation: The Declaration on Healthcare System Incentives PACBACK in JAMA (Bronfort et al. 2026) Cochrane Verdict on Spinal Manipulation (de Zoete et al. 2026) Trial Sequential Analysis: Research Waste (Elliott et al. 2026) Manual Therapy + Exercise (dos Santos et al. 2026) Patient Education for Chronic MSK Pain (Kongsted et al. 2026) Volume 1, Issue 2: Five Trials, 389 Patients, and What Threaded Carpal Tunnel Release Looks Like in 2026 (Ezenwanne et al. 2026) Return to Volume 1, Issue 1
Editorial Disclosure
The Forward Review is editorial commentary, not peer reviewed. Written by Jason Forward, DC, a licensed chiropractor at Vanguard Chiropractic in Tulsa, Oklahoma. Commentary reflects clinical and structural interpretation and does not represent the views of the original authors, Cochrane, the World Health Organization, or any institution.
Conflict of interest: Dr. Forward operates a cash-pay walk-in chiropractic clinic. He has a clinical and economic perspective on healthcare delivery models that informs commentary on how care is structured. The Declaration philosophy on vanguardchiro.com expands on this perspective. No financial relationships with the cited authors, Cochrane, the WHO, or any party.
Health policy commentary disclaimer. This article is editorial commentary on a published systematic review overview. Nothing here constitutes medical advice, healthcare policy advice, or a recommendation regarding specific health systems, payers, or care arrangements. Readers making clinical or policy decisions should consult relevant professionals.
Corrections policy: Errors are corrected with a dated correction notice appended to the article. Original text remains accessible via revision history.
Level of evidence: Cochrane overview of systematic reviews (25 reviews screened, 5 contributed, 3 with moderate to high AMSTAR 2 confidence on outcomes of interest).
April 25, 2026

Outcome	Opioid Group	Placebo Group
Mean pain (0 to 10)	2.78	2.25
Better physical function?	No advantage	No advantage
Better quality of life?	No advantage	No advantage
Faster recovery?	No advantage	No advantage

FR Specialty: Policy and Access

Key Points

Why This Question Matters

How the OPAL Trial Was Built

What Did OPAL Find at Six Weeks?

What Happened at One Year?

Does This Mean Opioids Are Useless for Every Kind of Pain?

What Do the Guidelines Say Now?

What This Means Clinically

For Recurring Mechanical Pain, Plan for It

Patient Translation: What to Do With a Badly Hurting Back

Walk in to Vanguard Chiropractic in Brookside

Frequently Asked Questions

Editorial Disclosure

Key Points

Why I Am Writing About a Procedure I Do Not Perform

What PRP Is and How It Is Supposed to Work

What This Meta-Analysis Did

How To Read These Numbers Without Getting Sold

Where PRP Sits in the Treatment Hierarchy for Low Back Pain

The Cost Question Nobody at the Injection Clinic Will Walk You Through

When PRP Probably Is the Right Move

What I Tell My Patients in My $40 Walk-In Clinic

Mechanism, Honestly Stated

Limitations and Caveats

The Tulsa Practical Read

Editorial Disclosure

Key Points

Why This Paper Matters

What the Study Did

What the Study Found

Mechanism and Clinical Context

Limitations and Caveats

What I Take From This for Practice

One: The pathway-of-care framing is worth taking seriously.

Two: The conservative-first care pathway has consistent evidence behind it, even when each individual piece is graded low or very low.

Three: The very-low certainty rating cuts against overclaiming, but it does not cut against the recommendation.

What the Review Does Not Resolve

Editorial Disclosure

Key Points

The Question

What They Found

The Bigger Finding Is in the Gaps

Why the Evidence Got Built the Way It Did

What This Means for Chiropractic Practice and Patients

Connecting to the Declaration

Editorial Disclosure